Odyssey Health Past Earnings Performance

Past criteria checks 3/6

Odyssey Health has been growing earnings at an average annual rate of 20.4%, while the Medical Equipment industry saw earnings growing at 11.3% annually.

Key information

20.4%

Earnings growth rate

23.1%

EPS growth rate

Medical Equipment Industry Growth	8.9%
Revenue growth rate	n/a
Return on equity	122.7%
Net Margin	n/a
Last Earnings Update	31 Jan 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Odyssey Health makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:ODYY Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Jan 24	11	4	0
31 Oct 23	-4	4	0
31 Jul 23	-6	5	0
30 Apr 23	-7	5	1
31 Jan 23	-9	7	1
31 Oct 22	-9	7	1
31 Jul 22	-8	7	1
30 Apr 22	-9	7	2
31 Jan 22	-19	6	2
31 Oct 21	-18	5	2
31 Jul 21	-17	5	2
30 Apr 21	-15	4	1
31 Jan 21	-4	3	0
31 Oct 20	-4	3	0
31 Jul 20	-4	4	0
30 Apr 20	-26	26	0
31 Jan 20	-25	25	0
31 Oct 19	-25	25	0
31 Jul 19	-23	23	0
30 Apr 19	0	0	0
31 Jan 19	0	0	0
31 Oct 18	0	0	0
31 Jul 18	0	0	0
30 Apr 18	0	0	0
31 Jan 18	0	0	0
31 Oct 17	0	0	0
31 Jul 17	0	0	0
30 Apr 17	0	0	0
31 Jan 17	0	0	0
31 Oct 16	0	0	0
31 Jul 16	0	0	0
30 Apr 16	0	0	0
31 Jan 16	0	0	0
31 Oct 15	0	0	0
31 Jul 15	0	0	0

Quality Earnings: ODYY has a large one-off gain of $15.1M impacting its last 12 months of financial results to 31st January, 2024.

Growing Profit Margin: ODYY became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ODYY has become profitable over the past 5 years, growing earnings by 20.4% per year.

Accelerating Growth: ODYY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ODYY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.9%).

Odyssey Health Past Earnings Performance

Past criteria checks 3/6

Key information

Recent past performance updates

Recent updates

Odyssey Health, Inc. announced delayed 10-Q filing

Oragenics, Inc. (NYSEAM:OGEN) completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Oragenics, Inc. (NYSEAM:OGEN) entered into an Asset Purchase Agreement to acquire Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.

Odyssey Health, Inc. Presents Concussion Treatment Data At the Military Health System Research Symposium -MHSRS

Odyssey Health, Inc. (OTCPK:ODYY) executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc.

Odyssey Health, Inc. Appoints Jeffrey Conroy as Director

Odyssey Health, Inc. to Develop Intranasal Field- Deliverable Nerve Agent Antidote

Odyssey Health, Inc. Announces Resignation of Jeffrey Conroy as Director

Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development

Odyssey Health, Inc., Annual General Meeting, Jan 12, 2023

Odyssey Health Inc. Announces Expansion of Executive Team

Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

Odyssey Health, Inc. Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II

Odyssey Health, Inc. Announces the Successful Completion of Safety Measures for Their Phase I Multi-Day Ascending Dosing (Mad) Clinical Trial

Odyssey Health, Inc. Announces Positive Results from its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug

Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug

Odyssey Health, Inc. Names Vice Admiral (r) Timothy Szymanski to the Military Advisory Board

Odyssey Group International Announces Formation of Military Advisory Board

Odyssey Group International, Inc. Continues Enrollment of its First in Kind Human Clinical Trial of its Proprietary Drug Compound Intended to Treat Concussion

Odyssey Group International, Inc. Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

Odyssey Group International, Inc. Approves to Start Human Trial to Treat Concussion

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion

Odyssey Group International, Inc. announced delayed 10-Q filing

Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion

Odyssey Group International, Inc. Announces the Completion of the Food and Drug Administration (FDA) Required Toxicology Studies Designed to Support Clinical Trials with Prv-002

Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate

Odyssey Group International, Inc. announced a financing transaction

Odyssey Group International, Inc. announced delayed annual 10-K filing

Odyssey Group International, Inc. announced that it expects to receive $10.6 million in funding from The EquiLux Group, LP, Lincoln Park Capital, LLC

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta